From its original 2010 approval through the 2025 Egrifta WR formulation, tesamorelin has established a clear regulatory pathway
Additionally, the LEADER study reported a post-hoc analysis in patients with polyvascular disease (defined as atherosclerosis in two or more of the following vasculature territories: ocular, coronary arteries, cerebral arteries or arteries peripheral), in which they did not observe significant differences in the risk of non-fatal stroke in the liraglutide group versus placebo [63]
Our team has administered over 100,000 IVs
7 A study presented at the 2026 American Society of Clinical Oncology reported a 34 percent lower risk of death across six cancer types for those taking GLP-1 drugs
Many GLP-1 medications can lead to meaningful weight loss, which can, in turn, improve insulin resistance and blood sugar levels